Mycamine Approval History 
- FDA approved: Yes (First approved March 16th, 2005)
- Brand name: Mycamine
- Generic name: micafungin sodium
- Company: Fujisawa Healthcare, Inc.
- Treatment for: Esophageal Candidiasis, Fungal Infection Prophylaxis, Candida Infections, Systemic
Mycamine (micafungin sodium) is an echinocandin antifungal agent used for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation, for the treatment of esophageal candidiasis and candidemia.
FDA Approval History for Mycamine
| Date | Article |
|---|---|
| Jan 23, 2008 |  FDA Approves Additional Indication for Astellas' Mycamine |
| Mar 16, 2005 | Mycamine Approved for Candida Infections |
| Apr 27, 2004 | Fujisawa Healthcare, Inc. Submits NDA For Mycamine For Treatment Of Esophageal Candidiasis |
See also...
Mycamine (micafungin sodium) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
